Table 3. Stage and adjuvant treatment decision between SLNB (only) versus SLNB + ALND.
| Z0011 eligible patients, n = 128 | |||
|---|---|---|---|
| Parameters | SLNB only | SLNB + ALND | Remarks |
| Nodal stage, n (%) | |||
| N1 | 128 (100) | 103 (80.5) | Nodal stage changed in 19.5%. |
| N2 | 0 | 24 (18.8) | |
| N3 | 0 | 1 (0.8) | |
| TNM stage (AJCC 7th), n (%) | |||
| Stage 2 | 128 (100) | 103 (80.5) | TNM stage changed in 19.5%. |
| Stage 3 | 0 | 25 (19.5) | |
| MDT decision (chemotherapy), n (%) | |||
| Yes | 115 (89.8) | 119 (93) | In 4/128 (3%), ALND changed the decision of chemotherapy. |
| No | 13 (10.2) | 9 (7) | |
| Z0011 eligible + mastectomy, n = 176 | |||
| Nodal stage, n (%) | |||
| N1 | 176 (100) | 143 (81.3) | Nodal stage changed in 18.7%. |
| N2 | 0 | 28 (15.9) | |
| N3 | 0 | 5 (2.8) | |
| TNM stage (AJCC 7th), n (%) | |||
| Stage 2 | 176 (100) | 143 (81.3) | TNM stage changed in 18.7%. |
| Stage 3 | 0 | 33 (18.7) | |
| MDT decision (chemotherapy), n (%) | |||
| Yes | 157 (89.8) | 161 (91.5) | In 4/176 (2.2%), ALND changed the decision of chemotherapy. |
| No | 19 (10.2) | 15 (8.5) | |
| MDT decision (Radiotherapy), n = 48, n (%) | |||
| Yes | 43 (89.6) | 43 (89.6) | No change |
| No | 5 (10.4) | 5 (10.4) | |
SLNB = Sentinel lymph node biopsy, ALND = Axillary lymph node biopsy, MDT = Multi-disciplinary team